Department of Infectious Disease, Peking University First Hospital, Beijing, China.
J Viral Hepat. 2010 Mar;17 Suppl 1:59-65. doi: 10.1111/j.1365-2893.2010.01272.x.
Early virological response is considered to be a predictor for the outcome of anti-hepatitis B virus (HBV) therapy. To analyze its correlation to intrahepatic HBV DNA and covalently closed circular DNA (ccc)DNA, 71 hepatitis B virus e antigen (HBeAg)-positive chronic hepatitis B patients were recruited: 34 patients were treated with lamivudine; 13 with interferon-alpha2b; and 24 with sequential therapy of lamivudine-interferon-alpha2b for 48 weeks. Intrahepatic HBV DNA and cccDNA load were measured at the baseline and at Week 48. Fifty-seven patients had virological response at Week 12. Median decreases of serum HBV DNA in patients with or without virological response at Week 12 were 4.0 log(10) (max. 6.2, min. 2.2) and 1.1 log(10) (max. 2.1, min. 0) (Z = -5.766, P = 0.0000), respectively. At Week 48 they were 4.1 log(10) (max. 7.4, min. 1.0) and 2.3 log(10) (max. 7.5, min. 0.3) (Z = -2.760, P = 0.006), respectively. For intrahepatic HBV DNA load they were 1.3 log(10) (max. 4.3, min. -1.2) and 0.6 log(10) (max. 3.5, min. -0.8), respectively, and for HBV cccDNA load they were 1.1 log(10) (max. 4.8, min. -0.5) and 0.5 log(10) (max. 3.0, min. -0.8) (Z = -2.097, P = 0.036), respectively at Week 48. Step-wise logistic regression analysis indicated that the baseline intrahepatic HBV DNA load effected virological response at Week 12 [odds ratio (OR) 0.405; 95% confidence interval (CI) 0.174-0.944; P = 0.036] and HBeAg seroconversion at Week 48 (OR 0.292; 95% CI 0.131-0.649; P = 0.003). In conclusion, virological response at Week 12 indicated a great reduction of intrahepatic DNA and cccDNA load in HBeAg-positive CHB patients. The baseline intrahepatic HBV DNA load affected virological response at Week 12 and HBeAg seroconversion at Week 48.
早期病毒学应答被认为是乙型肝炎病毒 (HBV) 治疗结果的预测因素。为了分析其与肝内 HBV DNA 和共价闭合环状 DNA (ccc)DNA 的相关性，招募了 71 例乙型肝炎病毒 e 抗原 (HBeAg) 阳性慢性乙型肝炎患者：34 例接受拉米夫定治疗；13 例接受干扰素-α2b 治疗；24 例接受拉米夫定-干扰素-α2b 序贯治疗 48 周。在基线和第 48 周测量肝内 HBV DNA 和 cccDNA 载量。第 12 周有 57 例患者发生病毒学应答。第 12 周有或无病毒学应答的患者血清 HBV DNA 中位数下降分别为 4.0 log(10) (最大值 6.2，最小值 2.2) 和 1.1 log(10) (最大值 2.1，最小值 0) (Z = -5.766，P = 0.0000)。第 48 周时，它们分别为 4.1 log(10) (最大值 7.4，最小值 1.0) 和 2.3 log(10) (最大值 7.5，最小值 0.3) (Z = -2.760，P = 0.006)。对于肝内 HBV DNA 载量，它们分别为 1.3 log(10) (最大值 4.3，最小值-1.2) 和 0.6 log(10) (最大值 3.5，最小值-0.8)，对于 HBV cccDNA 载量，它们分别为 1.1 log(10) (最大值 4.8，最小值-0.5) 和 0.5 log(10) (最大值 3.0，最小值-0.8) (Z = -2.097，P = 0.036)。第 48 周。逐步逻辑回归分析表明，基线肝内 HBV DNA 载量影响第 12 周的病毒学应答[比值比 (OR) 0.405；95%置信区间 (CI) 0.174-0.944；P = 0.036]和第 48 周的 HBeAg 血清学转换(OR 0.292；95%CI 0.131-0.649；P = 0.003)。总之，第 12 周的病毒学应答表明 HBeAg 阳性 CHB 患者肝内 DNA 和 cccDNA 载量有很大降低。基线肝内 HBV DNA 载量影响第 12 周的病毒学应答和第 48 周的 HBeAg 血清学转换。
